section name header

Pronunciation

kloe-MIP-ra-meen

Classifications

Therapeutic Classification: antiobsessive agents

Pharmacologic Classification: tricyclic antidepressants

Indications

BEERS REMS


Action

  • Potentiates the effect of serotonin (antiobsessional effect) and norepinephrine in the CNS. Has moderate anticholinergic effects.
Therapeutic effects:
  • Diminished obsessive-compulsive behavior.

Pharmacokinetics

Absorption: Well absorbed from the GI tract.

Distribution: Widely distributed to tissues.

Protein Binding: 90%.

Metabolism/Excretion: Mostly metabolized by the liver by the CYP2D6 isoenzyme; the CYP2D6 enzyme system exhibits genetic polymorphism; 7% of population may be poor metabolizers (PMs) and may have significantly clomipramine concentrations and an risk of adverse effects; .

Half-Life: 21–31 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
PO1–6 wkunknownunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ECG changes, ARRHYTHMIAS, orthostatic hypotension

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMATIC SYMPTOMS (DRESS), dry skin, photosensitivity

EENT: blurred vision, dry eyes, vestibular disorder

Endo: gynecomastia, syndrome of inappropriate antidiuretic syndrome (SIADH)

F and E: hyponatremia

GI: vomiting, constipation, dry mouth, nausea, eructation

GU: male sexual dysfunction, urinary retention

Hemat: anemia

Metab: weight gain

MS: muscle weakness

Neuro: sedation, weakness, aggressive behavior, extrapyramidal reactions, SEIZURES, SUICIDAL THOUGHTS

Misc: hyperthermia

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Anafranil